Title: 1) Founder, Chief Executive Officer and Chief Science Officer; 2) Owner
Company: 1) KeriCure Medical; 2) KeriChem Tech LLC
Location: Land O’ Lakes, Florida, United States
Kerriann R. Greenhalgh, PhD, founder, chief executive officer and chief science officer of KeriCure Medical and owner of KeriChem Tech LLC, has been recognized by Marquis Who’s Who Top Executives for dedication, achievements, and leadership in biotechnology.
Dr. Greenhalgh is a distinguished expert in biotechnology, nanotechnology and wound care. As the founder, chief executive officer and chief science officer of KeriCure Medical since 2011, she has been instrumental in developing and commercializing innovative wound care solutions. Her work focuses on expanding strategic partnerships and scouting acquisition partners while overseeing research and development, quality and regulatory aspects. Dr. Greenhalgh’s passion for creating new nanopolymer formulas and conducting clinical trials underscores her commitment to advancing wound healing technologies.
In addition to her role at KeriCure Medical, Dr. Greenhalgh owns KeriChem Tech LLC, a consulting company she founded in 2017 that provides clients with a range of development, testing and regulatory consulting services in the United States. Her firm notably specializes in biotechnology, medical devices, formulations and regulatory consulting, with a focus on 510k and new over-the-counter drug product development and transition to commercially viable products for market launch.
Dr. Greenhalgh’s career began as a graduate teaching assistant in the department of chemistry at the University of South Florida while pursuing her bachelor’s degree, where she later served as a professor from 2011 to 2012. She also gained valuable experience as a senior chemist at Constellation Technology in 2010 and as an interdisciplinary scientist with the Food and Drug Administration’s division of reproductive, abdominal and radiological devices. Dr. Greenhalgh’s early career also included roles as a biomedical engineer and senior project engineer at MiMedx Group between 2008 and 2010.
In preparation for her career in this sector, Dr. Greenhalgh earned a Bachelor of Arts in chemistry with an emphasis in biochemistry, magna cum laude, in 2004, followed by a Doctor of Philosophy in organic chemistry from the University of South Florida in 2007. Her graduate work led to developing a unique nanopolymer drug delivery system that became the basis for KeriCure’s technology platform.
Dr. Greenhalgh’s professional affiliations include membership in the Society of Advanced Wound Care, the Society of Toxicology, and the American Chemical Society. Her civic involvement includes mentoring nearly 40 students through KeriCure at the University of South Florida and supporting organizations like the Army Ranger Foundation and the Sentinel Foundation.
Beyond these affiliations, Dr. Greenhalgh’s dedication to advancing wound care is further evidenced by her numerous publications and presentations at conferences, such as the Military Health System Research Symposium and the Symposium on Advanced Wound Care. These opportunities serve as a testament to her expertise in the field.
Dr. Greenhalgh’s innovative nanopolymer drug delivery system earned her recognition among the top five finalists in the U.S. Army’s xTechSearch program in 2020, earning approximately $145,000 for her contributions to military medicine. Earlier, she was named a Quake Capital Cohort 4.0 Awardee in 2019. Dr. Greenhalgh also received several fellowships from the National Science Foundation-Integrative Graduate Education and Research Traineeship and the U.S. Department of Homeland Security.
Driven by a passion for addressing burn wounds, Dr. Greenhalgh is assembling a team to target advanced wound care markets, focusing on burn care products. Her ultimate goal is to ensure that soldiers have access to these products in their first aid kits, enabling them to provide immediate care on the battlefield.
For more information, please visit:
Contact Dr. Greenhalgh:
